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Summary
Background Available incidence data for invasive salmonella disease in sub-Saharan Africa are scarce. Standardised, 
multicountry data are required to better understand the nature and burden of disease in Africa. We aimed to measure 
the adjusted incidence estimates of typhoid fever and invasive non-typhoidal salmonella (iNTS) disease in sub-
Saharan Africa, and the antimicrobial susceptibility proﬁ les of the causative agents.
Methods We established a systematic, standardised surveillance of blood culture-based febrile illness in 13 African 
sentinel sites with previous reports of typhoid fever: Burkina Faso (two sites), Ethiopia, Ghana, Guinea-Bissau, Kenya, 
Madagascar (two sites), Senegal, South Africa, Sudan, and Tanzania (two sites). We used census data and health-care 
records to deﬁ ne study catchment areas and populations. Eligible participants were either inpatients or outpatients who 
resided within the catchment area and presented with tympanic (≥38·0°C) or axillary temperature (≥37·5°C). Inpatients 
with a reported history of fever for 72 h or longer were excluded. We also implemented a health-care utilisation survey 
in a sample of households randomly selected from each study area to investigate health-seeking behaviour in cases of 
self-reported fever lasting less than 3 days. Typhoid fever and iNTS disease incidences were corrected for health-care-
seeking behaviour and recruitment.
Findings Between March 1, 2010, and Jan 31, 2014, 135 Salmonella enterica serotype Typhi (S Typhi) and 94 iNTS 
isolates were cultured from the blood of 13 431 febrile patients. Salmonella spp accounted for 33% or more of all 
bacterial pathogens at nine sites. The adjusted incidence rate (AIR) of S Typhi per 100 000 person-years of observation 
ranged from 0 (95% CI 0–0) in Sudan to 383 (274–535) at one site in Burkina Faso; the AIR of iNTS ranged from 0 in 
Sudan, Ethiopia, Madagascar (Isotry site), and South Africa to 237 (178–316) at the second site in Burkina Faso. The 
AIR of iNTS and typhoid fever in individuals younger than 15 years old was typically higher than in those aged 
15 years or older. Multidrug-resistant S Typhi was isolated in Ghana, Kenya, and Tanzania (both sites combined), and 
multidrug-resistant iNTS was isolated in Burkina Faso (both sites combined), Ghana, Kenya, and Guinea-Bissau.
Interpretation Typhoid fever and iNTS disease are major causes of invasive bacterial febrile illness in the sampled 
locations, most commonly aﬀ ecting children in both low and high population density settings. The development of 
iNTS vaccines and the introduction of S Typhi conjugate vaccines should be considered for high-incidence settings, 
such as those identiﬁ ed in this study.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Salmonella infections contribute substantially to global 
morbidity and mortality.1,2 The best described invasive 
salmonella serovars are Salmonella enterica serotype Typhi 
(S Typhi), causing typhoid fever, and S enterica serotype 
Paratyphi A, B, and C (S Paratyphi A, B, and C), which 
cause paratyphoid fever. Other non-typhoidal salmonella 
(NTS) serovars that typically cause self-limiting diarrhoea 
can also cause systemic infections, refered to as invasive 
NTS (iNTS) disease.3 Globally, typhoid fever is estimated 
to cause 21·7 million illnesses and 217 000 fatalities 
annually, and iNTS disease is estimated to cause 
3·4 million illnesses and 681 000 fatalities annually.1,2
Substantial knowledge gaps exist regarding the 
distribution of typhoid fever and iNTS disease in Africa. 
The few existing studies,4–8 reported over diﬀ ering time 
periods and using various protocols, have been 
extrapolated and contribute to existing typhoid fever 
estimates, which limits international generalisability. 
The scarcity of data in sub-Saharan Africa prompted 
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WHO, in 2008, to request more epidemiological 
information to reliably estimate the incidence of 
typhoid fever and iNTS disease and the antimicrobial 
susceptibilities of the corresponding organisms.9 
Consequently, between 2010, and 2014, we established 
13 surveillance sites across sub-Saharan Africa in 
Research in context
Evidence before this study
We did a literature search using PubMed with the following 
search terms: (“typhoid” OR “typhoid fever” OR “Salmonella 
Typhi” OR “S Typhi” OR “salmonella infection” OR “enteric 
fever” OR “non-typhoidal salmonella” OR “NTS”) AND 
(“incidence”OR “rate” OR “frequency” OR “prevalence” OR 
“morbidity” OR “burden” OR “surveillance” OR “epidemiology”). 
We restricted publication dates from Dec 31, 1995, to July 30, 
2016, and no language restrictions were applied. The date of 
our last search was July 30, 2016.
Salmonella infections are a major cause of global morbidity and 
mortality; however, substantial knowledge gaps exist with 
regards to the distribution and incidence of disease caused by 
Salmonella enterica serotype Typhi and invasive non-typhoidal 
salmonella (iNTS) disease in sub-Saharan Africa.
Before the Typhoid Fever Surveillance in Africa Program (TSAP), 
estimates of typhoid fever incidence data from Africa were 
available from four vaccine trials and one population-based 
study in Kenya. Other estimates of invasive salmonella infections 
originated from diﬀ erent descriptions of bacteraemia in febrile 
patients in The Gambia, Malawi, Mozambique, and Kenya. These 
few, unstandardised, published data are not suﬃ  cient for 
understanding the burden of the disease in sub-Saharan Africa.
In 2008, WHO expressed the necessity for more epidemiological 
information to estimate the incidence and antimicrobial 
susceptibility of invasive salmonella disease. Consequently, in 
January, 2009, the International Vaccine Institute (Seoul, 
South Korea) and the Kenya Medical Research Institute (Kiliﬁ , 
Kenya) co-hosted a meeting with ﬁ ve other international 
institutions and 28 investigators from 14 research sites across 
sub-Saharan Africa. The purpose of the meeting was to review 
existing data on invasive salmonella infections in sub-Saharan 
Africa and surveillance infrastructure from sites, and to discuss 
the way forward to investigate invasive salmonella in the 
African region. These 28 investigators and the ﬁ ve international 
institutions presented their data on invasive bacterial disease, 
focusing on invasive salmonellosis.
The data indicated the presence of typhoid fever and iNTS 
disease; however, the studies were not standardised in design, 
data collection, and laboratory techniques. The meeting 
concluded that unless standardised methods of data collection 
and diagnostic procedure were used across countries, and 
patterns of health-care utilisation were understood and 
accounted for, the real disease burden of invasive salmonella 
infections in the region would remain unclear. As a result, a 
consortium was established and members agreed to form a 
network of surveillance sites in sub-Saharan Africa in areas with 
previous reports of cases of typhoid fever.
The TSAP was created to address the knowledge gaps on the 
incidence and antimicrobial resistance patterns of invasive 
salmonella infections at diﬀ erent countries with previous 
reports of typhoid fever cases in sub-Saharan Africa. TSAP 
created a network of 13 surveillance sites across ten countries, 
and implemented cross-sectional studies to investigate the 
health-care-seeking behaviour of the populations under 
surveillance. 
Added value of this study
Original data collected in TSAP represent the most comprehensive 
standardised analysis done in sub-Saharan Africa of the incidence 
and antimicrobial resistance patterns of invasive salmonella 
infections. The results describe the incidence estimated, adjusted 
by health-care-seeking behaviour, and antimicrobial susceptibility 
of typhoid fever and iNTS diseases from 13 sites in 
ten sub-Saharan Africa countries. For typhoid fever disease, we 
estimate that the overall incidence is two to three times higher 
than a previous estimate (10–100 cases per 100 000 people), and 
is in some settings similar to data from Asia, where the burden is 
known to be very high. The data also revealed that children aged 
2–14 years bear the greatest burden of the disease. For iNTS 
disease, the data also reﬂ ect a high incidence, especially in young 
children, and in speciﬁ c sites (Ghana) the incidence could be more 
than ﬁ ve times that previously estimated.
Implications of all the available evidence
The results of this study underscore the need for preventive 
measures, including vaccines, improved sanitation and hygiene, 
malaria control, antiretroviral therapy programmes, and 
improved nutrition. The results also emphasise that the 
implementation of eﬀ ective antimicrobials might be impaired by 
the presence and potential increase of drug-resistance 
salmonella strains in the region. The advent of typhoid conjugate 
vaccines might provide more powerful tools to control typhoid 
fever; the ﬁ rst vaccine, which was manufactured in India, has 
already been submitted to WHO for prequaliﬁ cation. Data from 
this study will be included in the GAVI Alliance review of 
potential subsidies for typhoid fever vaccines in 2017; their 
recommendation will be crucial for the deployment of these 
vaccines. Hence, an urgent need exists to understand the 
pragmatic aspects of vaccine targeting and delivery, particularly 
given the burden of disease in children, the associated risk 
factors, and the focal nature of the disease. Further assessment 
of the incidence in infants (0–5 months vs 6–11 months) and 
data on severe typhoid fever or iNTS, including mortality, is 
crucial to determine the potential eﬀ ect of future vaccines. Our 
follow-on study—Severe Typhoid in Africa (SETA)—which 
investigates severe typhoid burden, is underway. 
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locations where typhoid fever had been previously 
reported. This network formed the Typhoid Fever 
Surveillance in Africa Program (TSAP) and served as a 
platform to implement standardised surveillance of 
febrile illness and cross-sectional studies to investigate 
the health-care-seeking behaviour of the surveyed 
populations.10–12 Here, we present the adjusted 
incidence estimates of typhoid fever and iNTS disease 
and the antimicrobial susceptibility proﬁ les of the 
causative agents at the 13 selected surveillance sites.
Methods
Study design, site selection, and participants
We used a multicentre, population-based, prospective 
surveillance study design. Selection of the surveillance 
sites in sub-Saharan Africa was not random; locations 
were eligible if they had evidence of previous 
typhoid fever, a laboratory infrastructure suitable for 
blood culture, an onsite health-care facility, and staﬀ 
experienced in micro biological laboratory research.10 
13 sites in ten countries were selected (ﬁ gure 1), four of 
which already had established surveillance systems: 
Pietermaritzburg, South Africa; Asante Akim North, 
Ghana; Moshi Urban District and Moshi Rural District, 
Tanzania; and Kibera, Kenya. Four sites were part of the 
International Network for the Demographic Evaluation 
of Populations and Their Health (INDEPTH): Polesgo 
and Nioko II, Burkina Faso; Butajira, Ethiopia; and 
Bandim, Guinea-Bissau. These sites had functional 
Health and Demographic Surveillance Systems (HDSS) 
in place.13 Additional surveillance sites were Isotry and 
Imerintsiatosika, Madagascar; Pikine, Senegal; and East 
Wad Medani, Sudan. The surveillance system in Kibera 
was established before TSAP with an active, population-
based surveillance component. Home visits were done 
once every 2 weeks to screen for febrile patients and 
encourage visits to the aﬃ  liated health-care facility. 
Active surveillance in Kibera was continued throughout 
Figure 1: Sites participating in the Typhoid Fever Surveillance in Africa Program
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TSAP. All other sites implemented passive surveillance.10 
The ethics committees of all collaborating institutions 
and the International Vaccine Institute (Seoul, 
South Korea) approved the study protocol.
The catchment area for each site was determined 
through health-care facility records and through 
accessible administrative and demographic data.11 We 
determined the population of each catchment area using 
the latest census or the INDEPTH database. We 
categorised sites as urban, rural, or other using setting 
classiﬁ cations at each site. Surveillance was implemented 
in each study location for a period of at least 12 months 
and recruitment occurred at primary, secondary, and 
tertiary health-care facilities.
Recruitment was open to outpatients and inpatients 
who visited any of the health-care facilities participating 
in TSAP, who resided within the catchment area 
and presented with tympanic (≥38·0°C) or axillary 
temperature (≥37·5°C). Inpatients with a reported 
history of fever for 72 h or longer were excluded, as were 
patients with residence outside of the catchment area. 
Asante Akim North recruited children younger than age 
15 years only; other sites recruited patients of all ages. 
Written informed consent preceded recruitment and 
clinical appraisal forms were completed for all 
participants.
Laboratory procedures
We standardised laboratory, quality control, and blood 
sample collection procedures across sites.10 Blood 
(5–10 mL for adults; 1–3 mL for children) was inoculated 
into aerobic blood culture bottles and incubated in an 
automated blood culture system (BD BACTEC, Becton-
Dickinson, USA, or BacT/ALERT, BioMérieux, France), 
with the exception of Sudan, where manual culturing 
with daily subculturing for up to 5 days was instituted. 
Gram staining and bacterial identiﬁ cation were done 
with standard microbiological techniques.14 Quality 
control of preanalytical processes included time and 
temperature control measures, during which every blood 
culture bottle was collected, transported, and placed into 
the incubator. Quality control of analytical processes 
included sterility and function control of culture media, 
controls of biochemical reactions, and antimicrobial 
susceptibility testing. For the quality control of manual 
culturing in Sudan, additionally, blood culture bottles 
were inoculated weekly with a suspension containing 
Escherichia coli or Staphylococcus aureus references. 
Inoculated blood culture bottles were incubated 
overnight and veriﬁ ed for growth by subculture.
Contaminants were deﬁ ned as organisms not typically 
associated with bloodstream infections; these included 
non-pathogens and those more commonly associated 
with commensal skin microbiota, including coagulase-
negative Staphylococci, Bacillus spp, and Micrococcus spp. 
Antimicrobial susceptibility testing was done by disc 
diﬀ usion according to Clinical and Laboratory Standards 
Institute15 standards for ampicillin, amoxicillin-clavulanic 
acid, chloramphenicol, co-trimoxazole, ceftriaxone, and 
ciproﬂ oxacin. Multidrug resistance was deﬁ ned as 
resistance to ampicillin or amoxicillin-clavulanic acid, 
chloramphenicol, and co-trimoxazole. Isolates with 
intermediate susceptibility were classiﬁ ed as resistant. 
Malaria blood smears were routinely done, except in 
South Africa. In Ethiopia, rapid diagnostic tests (SD 
BIOLINE Malaria Ag Pf/Pv, SD Standard Diagnostics, 
Yongin, South Korea) were used in addition to routine 
malaria blood smears.
Figure 2: Visits to health-care facilities and recruitment of patients during surveillance period at each site
NA=not available. *Data on health facility visits were collected retrospectively, after completion of surveillance period. Diagnosis of febrile illnesses was used at sites when temperature of patients was not 
recorded. †Number estimated by the proportion of the population under demographic surveillance at each respective site. ‡In Tanzania, before Nov 11, 2011, every ﬁ fth eligible patient was recruited; from 
Nov 11, 2011, every second eligible patient was recruited. This recruitment pattern was applied to this number.  
Total patients recruited
from study area:
met inclusion criteria
(n=13 358)
Total patients analysed: 
resided in study area, 
met inclusion criteria,
AND had complete 
blood results
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NA‡ NA‡ NA‡
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Ethiopia Senegal South Africa
For the study protocol see 
http://www.ivi.int/?page_id= 
12479&uid=922&mod= 
document
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Health-care utilisation survey and person-years of 
observation calculation
The health-care-seeking behaviour of the populations 
under surveillance was investigated with the assumption 
that access to the TSAP health-care facility was non-
uniform throughout the population.16,17 A standardised 
and pretested health-care utilisation survey was 
implemented in a representative sample of households 
randomly selected from each study area.11 We investigated 
health-care-seeking behaviour in cases of self-reported 
fever lasting less than 3 days. The ﬁ rst choice of health-
care facility in cases of fever was categorised by age-
stratiﬁ ed groups and used to calculate the proportion of 
individuals from the catchment population who visited 
this TSAP health-care facility. This proportion constituted 
an adjustment factor to correct incidences. The time at 
risk in person-years of observation (PYO) stratiﬁ ed by 
age was calculated using the adjusted population. In 
HDSS sites, each resident contributed to PYO for the 
time present in the study area during the recruitment 
period. In non-HDSS sites, we calculated PYO by 
projecting the catchment population from the start to the 
end of the study recruitment period, and multiplied the 
calculated average population by the number of years of 
surveillance duration.
Statistical analysis
We established a multicountry database using FoxPro 
software. We excluded patients from the analysis who were 
recruited during pilot testing, failed to meet inclusion 
criteria, or had incomplete laboratory results. We estimated 
incidences per 100 000 PYO. Conﬁ rmed invasive 
salmonella cases, stratiﬁ ed by age group (0–1 years, 
2–4 years, 5–14 years, and ≥15 years), were adjusted by the 
speciﬁ c age-group recruitment proportion. We calculated 
this proportion by dividing the number of patients with 
complete data (numerator) by the total number of patients 
in the study area who had been diagnosed with a febrile 
illness at a recruitment facility during the surveillance 
period (denominator). We used health-care facility records, 
reviewed at the end of the surveillance activities, to 
estimate the number of patients diagnosed with a febrile 
illness. The catchment population in PYO, adjusted by 
health-care-seeking behaviour, was used as the 
denominator in crude and adjusted incidence rates (AIR).
The 95% CI for AIR was derived on the log-scale 
and exponentiated. We used the error factor 
(exp[1·96/√adjusted cases]) to calculate the lower (adjusted 
rate/error factor) and upper (adjusted rate × error factor) 
95% CIs. At the sites in Senegal, Ethiopia, and 
South Africa, incomplete health-care facility records did 
not allow for the estimation of the recruitment proportion 
and calculation of AIRs; for these sites we present crude 
rates. AIRs for typhoid fever and iNTS were assessed for 
all other sites. Diﬀ erences in proportions of blood cultures 
positive for a pathogen between study years were assessed 
with the χ² test (SAS, version 9.3).
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between March 1, 2010, and Jan 31, 2014, we recruited 
13 558 patients from 13 sites who met the inclusion 
criteria and resided in the catchment areas (ﬁ gures 1, 2). 
We excluded data from 127 (1%) patients because of 
incomplete laboratory results; data from 13 431 patients 
were analysed, and 8582 patients (64%) were younger 
than 15 years (table 1). All patients had one blood culture 
sample analysed at recruitment and 11 421 (85%) were 
screened for malaria parasites (table 1). The proportion 
of contaminated blood cultures ranged from less than 
1% in Imerintsiatosika to 24% in Nioko II. The 
proportion of blood cultures that yielded non-
contaminant bacteria varied between sites, ranging 
from 1% in Imerintsiatosika to 9% in Kibera (table 1). In 
total, 568 non-contaminant bacteria were isolated from 
blood samples of febrile patients. The most frequent 
non-contaminant bacteria isolated were S Typhi 
(135 [24%]), NTS (94 [17%]), S aureus (70 [12%]), E coli 
(47 [8%]), and Streptococcus pneumoniae (43 [8%]). Of the 
sites with at least 2 years of surveillance (Asante Akim 
North, Kibera, and Pietermaritzburg), the proportion of 
blood cultures that were pathogen positive diﬀ ered 
signiﬁ cantly between study years in Kibera only (12% at 
year 1 and 5% at year 2; p<0·0001; χ² test).
With the exception of East Wad Medani, Salmonella 
spp were isolated from the blood of febrile patients at all 
sites (135 S Typhi and 94 iNTS isolates), which accounted 
for 33% or more of all isolated bacteria in all but four 
sites (East Wad Medani, Pietermaritzburg, Butajira, and 
Isotry). Seasonal variation was not observed at any site 
(data not shown). The most common iNTS serovars 
were S enterica serotype Typhimurium (38 [40%] of 94), 
S enterica serotype Enteriditis (11 [12%] of 94), and 
S enterica serotype Dublin (10 [11%] of 94). The highest 
AIRs for typhoid fever in the 15 years or younger age 
group were observed in Polesgo, Kibera, and Asante 
Akim North (table 2). S Paratyphi A (three isolates) was 
isolated in Senegal only.
Among age groups of children younger than 15 years, 
the highest AIR for typhoid fever was observed in 
children aged 2–4 years from Polesgo, Asante Akim 
North, Moshi Urban District, and Kibera, and in 
children aged 5–14 years from Kibera and Polesgo 
(table 2). The AIR for typhoid fever in adults (aged 
≥15 years) was less than 70 per 100 000 PYO at all sites 
except Moshi Urban District, Kibera, and Polesgo 
(table 2).
iNTS organisms were more frequently isolated from 
infants (0–1 years) or children aged 2–4 years than from 
adults (table 2), except for the sites in Pikine, Moshi 
Rural District, and Kibera. The AIR for iNTS among 
children aged 2–4 years was highest in Nioko II, 
Polesgo, and Asante Akim North. The AIR for iNTS in 
children younger than 15 years was less than 100 per 
100 000 PYO in Kibera, Imerintsiatosika, and in both 
sites in Tanzania. No iNTS was isolated from sites in 
Sudan, South Africa, Ethiopia, and Isotry.
The antimicrobial susceptibility proﬁ les of S Typhi 
and iNTS isolates diﬀ ered between sites (table 3). 
Overall, 47% of S Typhi isolates and 48% of iNTS isolates 
were multidrug resistant. Most multidrug-resistant 
S Typhi isolates were obtained at the sites in Kenya, 
Ghana, and Tanzania (both sites combined). Multidrug-
resistant iNTS isolates were isolated at the sites 
in Burkina Faso (both combined), Ghana, Guinea-
Bissau, and Kenya (table 3). S Typhi isolates that had 
reduced ciproﬂ oxacin susceptibility were cultured in 
Kenya and South Africa, only; one ciproﬂ oxacin-
resistant S Paratyphi A organism was isolated in 
Senegal. Ciproﬂ oxacin-resistant iNTS was similarly 
uncommon, isolated only in Burkino Faso (once at the 
Nioko II site) and in Ghana. One iNTS isolate in Kenya 
was resistant to ceftriaxone (table 3).
Discussion
This study identiﬁ ed Salmonella as a major cause of 
invasive bacterial febrile illness across sub-Saharan 
Africa, aﬀ ecting children aged 2–14 years rather than 
adults, and arising in both high-population and low-
population density settings. Other major causes of 
invasive bacterial febrile illnesses varied by country; 
E coli and S aureus were the most frequent non-
Salmonella pathogens isolated from blood.
Results from previous studies18,19 suggest that typhoid 
fever in some sub-Saharan Africa settings occurs 
predominately in urban settlements with high-
population densities, and that disease incidence could 
have been overestimated by the use of the Widal test. 
Our study, done using a standardised protocol in both 
urban and rural settings, indicated high incidences of 
typhoid fever and iNTS in areas with high-population 
and low-population densities. Separate analyses done at 
the Ghana site conﬁ rmed this observation and revealed 
a higher disease incidence in children living in rural 
areas than in those living in urban areas.20 Furthermore, 
we observed variable incidences of typhoid fever and 
iNTS among neighbouring populations in Burkina Faso, 
and in the same populations in Kenya and Ghana in 
consecutive years, indicating a focal nature and a 
ﬂ uctuating burden of iNTS disease.
A previous global estimate of the burden of typhoid 
fever indicated that south-central and east-central Asia 
had the highest incidences of typhoid fever with more 
than 100 cases per 100 000 people annually; Africa was 
estimated to have a medium incidence (10–100 cases 
per 100 000).1 The AIR for typhoid fever estimated in our 
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study reveals a higher burden than previously estimated.1 
Four sites had an overall AIR for typhoid fever of more 
than 100 per 100 000 PYO, ﬁ ve sites had an AIR for typhoid 
fever of more than 100 per 100 000 PYO in children 
younger than 15 years, and six sites had an AIR for typhoid 
fever of more than 100 per 100 000 PYO in at least one age 
group. Similar to the Diseases of the Most Impoverished 
programme done in Asia,21 our results show that children 
aged 2–14 years bear the greatest burden of typhoid fever. 
Notably, our data indicate that the AIR for typhoid fever at 
TSAP sites was equal to or even greater than incidences 
reported in ﬁ ve Asian countries in the early 2000s.21,22
For iNTS disease, we observed an AIR equal or higher 
than previously estimated and a bimodal age distribution 
with very young children and adults being the key age 
group for symptomatic infection.2 This age distribution 
diﬀ ered from that observed for typhoid fever, in which 
children aged 2–14 years were the most aﬀ ected, and 
emphasises substantial diﬀ erences in the epidemiology 
of typhoid fever and iNTS disease. Malaria, malnutrition, 
and HIV infections have been reported to be associated 
with iNTS disease in Africa.23 At TSAP sites, a higher AIR 
for iNTS was observed in children with a malaria 
positivity rate of 30% or more than in those with a lower 
positivity rate; this observation was conﬁ rmed in a 
separate analysis.24
Results of our study identiﬁ ed a high prevalence of 
resistance against ﬁ rst-line antimicrobials in both 
S Typhi and iNTS infections. Reduced susceptibility to 
ciproﬂ oxacin was identiﬁ ed in S Typhi from Kibera and 
Pietermaritzburg. Multidrug-resistant iNTS isolates 
were isolated at several sites and have been isolated in 
sub-Saharan Africa previously.18,25,26 Furthermore, a 
single iNTS isolate from Kibera showed resistance to 
ceftriaxone. Genomic analyses27 have described the 
spread of S Typhi haplotype H58 into Africa, a multidrug-
resistant strain associated with reduced ciproﬂ oxacin 
susceptibility. The susceptibility patterns observed in 
our study are concerning, particularly because some 
anti microbial-resistant S Typhi can have a selective 
ﬁ tness advantage.28 Concerted measures are needed to 
monitor the emergence of ﬂ uoroquinolone-resistant 
Salmonella.29–32
We made all eﬀ orts to minimise bias; however, our 
study has some limitations. First, we did not adjust the 
disease incidences for blood culture sensitivity, which is 
approximately 40–60% of bone marrow culture.33–37 This 
correction factor is inconsistently applied in studies 
and, if applied here, the incidences presented would 
double. The restricted sensitivity of blood culture to 
detect Salmonella pathogens applies to other bacterial 
pathogens as well—ie, S pneumoniae and Haemophilus 
inﬂ uenzae type b—however, those are universally 
recognised as important infections for which vaccines 
are cost-eﬀ ective, and vaccination programmes have 
been established. Second, our results represent 
incidence in sites selected because of their previous 
reports on typhoid fever. The site selection strategy 
limits the generalisability of the AIR to other locations 
and might result in the reduced detection of iNTS 
Burkina Faso Guinea-Bissau Senegal* Ghana Ethiopia Madagascar South Africa Tanzania Kenya All
Total S Typhi isolates, N 18 3 7 30 3 9 2 9 54 135
Isolate with antimicrobial resistance, n (%)†
Ampicillin 0 NR NR 20 (67%) 2 (67%) NR 0 8 (89%) 41 (76%) 71 (53%)
Amoxicillin-clavulanic acid 0 NR NR 3 (10%) 0 NR 0 4 (44%) 24 (44%) 31 (23%)
Chloramphenicol 2 (11%) NR NR 23 (77%) 0 NR 0 5 (56%) 43 (80%) 73 (54%)
Co-trimoxazole 2 (11%) NR NR 24 (80%) 0 NR 0 8 (89%) 43 (80%) 77 (57%)
Ceftriaxone 0 NR NR 0 0 NR 0 0 0 0
Ciproﬂ oxacin 0 NR NR 0 0 NR 1 (50%) 0 11 (20%) 12 (9%)
Multidrug resistance‡ 0 NR NR 19 (63%) 0 NR 0 5 (56%) 40 (74%) 64 (47%)
Total iNTS isolates, N 14 8 4 59 0 1 0 2 6 94
Isolate with antimicrobial resistance, n (%)†
Ampicillin 10 (71%) 1 (13%) NR 38 (64%) NR NR NR 0 2 (33%) 51 (54%)
Amoxicillin-clavulanic acid 3 (21%) 0 NR 9 (15%) NR NR NR 0 2 (33%) 14 (15%)
Chloramphenicol 12 (86%) 1 (13%) NR 34 (58%) NR NR NR 0 1 (17%) 48 (51%)
Co-trimoxazole 13 (93%) 1 (13%) NR 34 (58%) NR NR NR 0 2 (33%) 50 (53%)
Ceftriaxone 0 0 NR 0 NR NR NR 0 1 (17%) 1 (1%)
Ciproﬂ oxacin 1 (7%) 0 NR 2 (3%) NR NR NR 0 0 3 (3%)
Multidrug resistance‡ 10 (71%) 1 (13%) NR 33 (56%) NR NR NR 0 1 (17%) 45 (48%)
Resistant isolates are reported per country, rather than per site. No Salmonella enterica serotype Typhi (S Typhi) or iNTS isolates were cultured in Sudan. iNTS=invasive non-typhoidal salmonella. NR=no resistant 
isolates identiﬁ ed. *Seven S Typhi, four iNTS, and three S enterica serotype Paratyphi (S Paratyphi) isolates. One of the S Paratyphi isolates was resistant to ciproﬂ oxacin. †Includes isolates fully and intermediately 
resistant against the respective drug, as deﬁ ned by the Clinical Laboratory and Standards Institute guidelines 2013.15 ‡Deﬁ ned as resistance against ampicillin or amoxicillin AND chloramphenicol AND 
co-trimoxazole.
Table 3: Antimicrobial resistance patterns of Salmonella enterica serotype Typhi and iNTS isolates across sites
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disease. Third, given the vast number of patients (and 
restricted diagnostics capacity), not every patient with a 
history of fever was enrolled—eg, at sites where 
inpatients were recruited, patients with a fever for 72 h 
or longer were excluded to minimise the inclusion of 
patients pretreated with antimicrobials and to maximise 
blood culture yield. Fourth, the proportion of the 
catchment population using the TSAP health-care 
facilities for febrile illness was low in some sites, and 
antimicrobial treatment before blood collection and its 
potential eﬀ ect on blood culture sensitivity were not 
assessed. Fifth, the classiﬁ cation of the settings as either 
urban, rural, semi-urban, or urban-slum reﬂ ects the 
classiﬁ cation commonly used at each site and does not 
refer to a standard deﬁ nition; instead, the population 
density of each site is presented to make setting 
comparisons. Sixth, sites with no previous experience of 
blood collection for blood culture assessment had a 
higher incidence of contamination than sites with 
previous experience of blood collection (South Africa, 
Ghana, Tanzania, and Kenya); these incidences might 
have led to errors in clinical interpretation and 
uncertainty to distinguish between clinically signiﬁ cant 
bacteraemia and contamination. Available isolates and 
blood samples collected from participants were PCR 
tested at the reference lab to minimise misclassiﬁ cation 
of isolated organisms. Seventh, the site in Ghana 
recruited only children younger than 15 years and the 
proportion of recruited inpatients varied greatly across 
all sites. Finally, data on disease severity, complications, 
mortality, and HIV status were not assessed because 
these were not primary study objectives. Despite these 
limitations, this multisite study, the largest study of 
typhoid fever and iNTS done across sub-Saharan Africa 
to date, provides the most current and accurate 
incidence ﬁ gures for these major infectious diseases 
across the continent and has substantial implications 
for their control.
We surmise that the incidence of invasive salmonella 
infections among children in sub-Saharan Africa is 
much higher than previously estimated, underscoring 
the need for preventive measures. Therefore, until access 
to safe drinking water and improved sanitation is greatly 
expanded, the prevention of typhoid fever will require 
immunisation and eﬀ ective treatment options.38 The 
advent of new typhoid fever conjugate vaccines might 
provide more powerful tools for disease control; the ﬁ rst 
typhoid fever conjugate vaccine (Bharat Biotech, 
Hyderabad) has been submitted to WHO for 
prequaliﬁ cation. Data from TSAP will be incorporated 
into the GAVI Alliances’ review of potential subsidies for 
typhoid fever vaccines in 2017; their recommendation 
will be crucial for deployment of these vaccines. Hence, 
the need to understand the pragmatic aspects of vaccine 
targeting and delivery is pressing, particularly given the 
burden of disease in children, the associated risk factors, 
and the focal and unpredictable nature of the disease. 
Similarly, in the absence of vaccines targeting iNTS 
disease, prevention will require a major investment in 
infrastructure for diagnosis and eﬀ ective treatment of 
iNTS disease. When appropriate diagnosis and treatment 
are available, the use of eﬀ ective antimicrobials might be 
impaired by the presence and potential increase of 
multidrug-resistant salmonella. Further assessment of 
incidences in infants (0–5 months vs 6–11 months) and 
data on severe typhoid fever or iNTS, including mortality, 
is crucial to determine the potential eﬀ ect of future 
vaccines. We are currently undertaking a follow-on 
study—Severe Typhoid in Africa (SETA)—which 
investigates severe typhoid burden.
We conclude that typhoid fever and iNTS disease are 
major agents of invasive bloodstream infections in 
urban and rural locations, aﬀ ecting children more 
commonly than adults across sub-Saharan Africa. 
Immunisation of high-risk age groups with existing 
and new vaccines should be a priority. The next 
generation of epidemiological studies in sub-Saharan 
Africa needs to provide better data regarding the 
severity and mortality of typhoid fever and iNTS to 
guide the introduction of new typhoid and iNTS 
vaccines. Lastly, the accelerated development and 
introduction of iNTS vaccines needs to become a 
fundamental goal on the global health agenda.
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